Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery
Listen to our talk at ELRIG Drug Discovery Digital to learn how bit.bio’s opti-ox™ technology can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.
Dr Thomas Moreau | Head of Research | bit.bio
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
bit.bio talk at ELRIG Drug Discovery Digital